Fresenius snaps up Akorn, Merck KGaA's biosimilars in separate deals
April 24, 2017 at 17:18 PM EDT
FRANKFURT, April 24 (Reuters) - Acquisitive German healthcare conglomerate Fresenius SE & Co KGaA revved up its deals pace by acquiring U.S. generic drugmaker Akorn Inc for $4.75 billion (4.37 billion euros), and in a separate deal, the biosimilars unit of German peer Merck KGaA .
